Features

Earning approval to use a new cardiovascular drug in the clinical setting can cost 100+ times the average of bringing other medications to market.  

Telehealth enthusiasts are optimistic about telestenting’s potential to solve access-to-care issues but concede that significant obstacles must be overcome before it will be ready for prime time.

Clinical trials presented at ACC.19 flipped the script on TAVR vs. SAVR. 

The global market for transcatheter treatment of the mitral and aortic valves is expected to increase from $4 billion to $8 billion in the next five years, but barriers exist. 

While the clinical case for cardiac PET is compelling, it also has to be feasible from a financial and logistical standpoint.

SCAI has diversified its planning committees and expanded the focus on live cases for its 2019 scientific sessions, says Program Chair Sunil Rao, MD.

Addressing social determinants of health improves outcomes, possibly providing a return on investment. Margins matter, but it’s a long game, often driven by a sense of mission.

Receiving payments from industry influenced physicians’ device selection but not patient outcomes, according to researchers who analyzed three years of Open Payment Program data.

As new hardware and software are introduced into interventional suites, imaging labs and surgical theaters, who bears responsibility for bringing medical personnel up to speed on the advantages they could deliver for safety and efficacy?

Geisinger is aiming to offer DNA sequencing to all of its 1.5 million patients. Members of its precision health team reveal how the initiative developed and share insights gleaned so far, challenges ahead and questions still to be answered.

A new stem cell-based test may add certainty to efforts to predict whether so-called variants of uncertain significance will contribute to the development of diseases or be harmless. 

Coronary artery calcium scanning is not a Magic 8 Ball, but it is a powerful predictor and a valuable tool for cardiology practices.